Latest news
Tango hopes it takes two: vopimetostat combos build on Revolution's pancreatic cancer breakthrough - FirstWord PharmaFirstWord Pharma · Thu, 06 Aug 2026 14:48:37 GMTImmuneering Reports 17.3-Month Median Overall Survival in First-Line Pancreatic Cancer and Progresses Phase 3 MAPKeeper 301 Trial - Quiver QuantitativeQuiver Quantitative · Wed, 05 Aug 2026 11:43:00 GMT